Why Amgen Stock Popped by 4% Today
Following quite encouraging news from the laboratory on Monday, (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development. With that share price rise, Amgen easily beat the S 500 index, which slid by 0.1%.
That news concerned Amgen's investigational stomach cancer drug, bemarituzumab. The company announced Monday that, in combination with chemotherapy, the treatment met its primary endpoint of of overall survival for the patients tested in a phase 3 clinical trial. It compared favorably to the results of patients only taking a placebo and receiving chemotherapy.
Image source: Getty Images.
Source Fool.com
Amgen Inc. Aktie
Hohe Buy- und niedrige Sell-Zahlen bei Amgen Inc. zeigen ein stark positives Sentiment.
Ein prognostiziertes Kursziel von 318 € für Amgen Inc. zeigt ein Potenzial von über 20% im Vergleich zum aktuellen Kurs von 251.9 €.
